¼¼°èÀÇ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå º¸°í¼­(2025³â)
Propionic Acidemia Global Market Report 2025
»óǰÄÚµå : 1731008
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ¾ÈÁ¤µÈ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 4.4%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 24¾ï 9,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ÀÎÁöµµ Çâ»ó Ä·ÆäÀÎ È®´ë, ´ë»ç ÀÌ»ó »ç·Ê ¼ö Áõ°¡, ¿ø°ÝÀÇ·á ä¿ë È®´ë, ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÇコÄɾî ÅõÀÚ Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿Çâ¿¡´Â Áø´ÜÀÇ ±â¼úÀû Áøº¸, À¯ÀüÀÚ Ä¡·á °³¹ß, ´ë»ç Ä¡·á Çõ½Å, ÇコÄɾ¼­ AI ÅëÇÕ, ½Å±Ô Ä¡·áÁ¦ âÃâ µîÀÌ Æ÷ÇԵ˴ϴÙ.

À¯Àü ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯Àü ÁúȯÀº °³ÀÎÀÇ DNA º¯À̳ª ÀÌ»ó¿¡ ÀÇÇØ ¹ß»ýÇÏ´Â º´ÅÂÀ̸ç, À¯ÀüµÇ´Â °æ¿ìµµ ÀÖ°í ÀÚ¿¬ÀûÀ¸·Î ¹ß»ýÇÏ´Â °æ¿ìµµ ÀÖ¾î °Ç°­°ú °³¹ß¿¡ ¿µÇâÀ» ÁÝ´Ï´Ù. À¯Àü Áúȯ Áõ°¡ÀÇ ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ¿­¼º À¯ÀüÀÚÀÇ µ¹¿¬º¯À̸¦ ¹°·Á¹ÞÀ» °¡´É¼ºÀ» ³ôÀÌ´Â ±ÙģȥÀÔ´Ï´Ù. ÀÌ´Â °áÇÔÀÌ ÀÖ´Â À¯ÀüÀÚ¸¦ ºÎ¸ð·ÎºÎÅÍ ¹°·Á¹ÞÀ¸¸é¼­ ¹ß»ýÇØ À¯Àü ÁúȯÀÇ À§ÇèÀ» ÇöÀúÈ÷ ³ôÀÔ´Ï´Ù. ÇÁ·ÎÇǿ»êÇ÷ÁõÀº ´ë»ç ºÒ±ÕÇü¿¡ ´ëóÇϰí ȯÀÚÀÇ Àü±Í¸¦ °³¼±Çϴ ǥÀûÄ¡·á¸¦ Á¦°øÇÔÀ¸·Î½á À¯Àü Áúȯ °ü¸®¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 7¿ù ¹Ì±¹ ºñ¿µ¸®´ÜüÀÎ ³¶Æ÷¼º¼¶À¯Áõ(CF)Àç´ÜÀÌ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é ³¶Æ÷¼º¼¶À¯Áõ À¯º´·üÀº Áõ°¡Çϰí ÀÖÀ¸¸ç, 2022³â¿¡´Â ¹Ì±¹¿¡¼­ ¾à 4¸¸ ¸íÀÇ ¾î¸°ÀÌ¿Í ¼ºÀÎÀÌ ÀÌȯµÇ¾ú°í, Àü ¼¼°èÀûÀ¸·Î´Â 10¸¸ 5õ ¸í ÀÌ»óÀÌ Áø´ÜµÇ¾ú½À´Ï´Ù. ±× °á°ú À¯Àü ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀåÀÇ È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

ÇÁ·ÎÇǿ»êÇ÷Áõ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Áúº´ÀÇ À¯ÀüÀû ¿øÀÎÀ» Á÷Á¢ Ç¥ÀûÀ¸·Î ÇÏ´Â Çõ½ÅÀûÀÎ mRNA ±â¹Ý Ä¡·á¹ýÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. mRNA Ä¡·á¹ýÀº ¸Þ½ÅÀú RNA¸¦ »ç¿ëÇÏ¿© À¯ÀüÀÚ ¼öÁØ¿¡¼­ ÁúȯÀ» ¿¹¹æ ¶Ç´Â Ä¡·áÇÒ ¼ö ÀÖ´Â ´Ü¹éÁúÀÇ »ý»êÀ» ¼¼Æ÷¿¡ Áö½ÃÇÔÀ¸·Î½á ±â´ÉÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 5¿ù ¹Ì±¹ Á¦¾à ¹× ¹ÙÀÌ¿À ±â¼ú ±â¾÷ÀÎ Moderna»ç´Â ÇÁ·ÎÇǿ»êÇ÷Áõ¿¡ ´ëÇÑ Ä¡Çè¿ë mRNA ¿ä¹ýÀÎ mRNA-3927ÀÇ 1/2»ó ½ÃÇè Áß°£ µ¥ÀÌÅ͸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Ä¡·á¹ýÀº mRNA¸¦ ÅëÇØ PCCA ¹× PCCB À¯ÀüÀÚÀÇ ±â´ÉÀû »çº»À» Àü´ÞÇÏ¿© °£ È¿¼Ò Ȱ¼ºÀ» ȸº¹½ÃŰ°í ´ë»ç¼º ±â´É ÀúÇϸ¦ ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ÃÖ÷´Ü Á¢±Ù¹ýÀº ÁúȯÀÇ À¯ÀüÀû ±Ùº» ¿øÀο¡ ´ëóÇÔÀ¸·Î½á ȯÀÚÀÇ Àü±Í¸¦ °³¼±Çϰí, ÀÌ Èñ±ÍÇÑ ´ë»ç¼º Áúȯ¿¡ °É¸° »ç¶÷µé¿¡°Ô »õ·Î¿î Èñ¸ÁÀ» Á¦°øÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-°Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Propionic acidemia (PA) is a rare inherited metabolic disorder caused by a deficiency of the enzyme propionyl-CoA carboxylase, which is crucial for breaking down specific amino acids and fatty acids. This deficiency results in the accumulation of toxic compounds in the blood, leading to severe symptoms such as metabolic crises and neurological damage. If left untreated, the condition can be life-threatening, particularly during infancy.

The primary drug classes used for treating propionic acidemia include L-carnitine and antibiotics. L-Carnitine is a naturally occurring compound that plays a vital role in transporting long-chain fatty acids into mitochondria, where they undergo oxidation to generate energy. Treatment can be administered through various routes, including oral, intravenous, and intramuscular methods. These medications are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The propionic acidemia market research report is one of a series of new reports from The Business Research Company that provides propionic acidemia market statistics, including propionic acidemia industry global market size, regional shares, competitors with a propionic acidemia market share, detailed propionic acidemia market segments, market trends and opportunities, and any further data you may need to thrive in the propionic acidemia industry. This propionic acidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The propionic acidemia market size has grown steadily in recent years. It will grow from $2.00 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth during the historic period can be attributed to factors such as the increasing prevalence of the disease, expansion of newborn screening programs, rising healthcare expenditures, a higher rate of pediatric diagnoses, and the advancement of rare disease initiatives.

The propionic acidemia market size is expected to see steady growth in the next few years. It will grow to $2.49 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The projected growth during the forecast period can be attributed to factors such as expanding awareness campaigns, a rising number of metabolic disorder cases, increased adoption of telemedicine, growing demand for personalized treatments, and increased healthcare investments. Key trends expected in this period include technological advancements in diagnostics, the development of gene therapies, innovations in metabolic treatments, the integration of AI in healthcare, and the creation of novel therapeutics.

The increasing prevalence of genetic disorders is expected to drive the growth of the propionic acidemia market. Genetic disorders are conditions caused by mutations or abnormalities in an individual's DNA, which may be inherited or occur spontaneously, impacting health and development. One of the key factors contributing to the rise in genetic disorders is consanguineous marriages, which increase the likelihood of inheriting recessive genetic mutations. This occurs when defective genes are passed down from both parents, significantly raising the risk of genetic conditions. Propionic acidemia plays a crucial role in managing genetic disorders by providing targeted treatments that address metabolic imbalances and improve patient outcomes. For example, in July 2022, a report published by the Cystic Fibrosis (CF) Foundation, a US-based non-profit organization, indicated that the prevalence of cystic fibrosis had increased, affecting nearly 40,000 children and adults in the United States in 2022, with over 105,000 individuals diagnosed globally. Consequently, the growing prevalence of genetic disorders is fueling the expansion of the propionic acidemia market.

Leading companies in the propionic acidemia market are focusing on the development of innovative mRNA-based treatments to directly target the genetic causes of the disease. mRNA therapies function by using messenger RNA to instruct cells to produce proteins that can prevent or treat diseases at the genetic level. For example, in May 2023, Moderna, a US-based pharmaceutical and biotechnology company, shared interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia. This therapy delivers functional copies of the PCCA and PCCB genes via mRNA, restoring enzyme activity in the liver and potentially reducing metabolic decompensations. This cutting-edge approach aims to enhance patient outcomes by addressing the genetic root cause of the disease, offering new hope for those affected by this rare metabolic disorder.

In May 2023, Ironwood Pharmaceuticals Inc., a US-based biotechnology company, acquired VectivBio for approximately $1 billion. Through this acquisition, Ironwood aims to strengthen its pipeline for rare diseases by integrating VectivBio's innovative therapies, including investigational treatments for propionic acidemia. VectivBio, a Switzerland-based biotechnology company, specializes in developing treatments for rare gastrointestinal and metabolic disorders.

Major players in the propionic acidemia market are Moderna Therapeutics, Synlogic Therapeutics, Invitae Corporation, Global Calcium, BridgeBio Pharma, AdvaCare Pharma, HemoShear Therapeutics, DNA Labs, Velnex Medicare, Phytologix Life Scieneces, Liaoning Koncepnutra Co. Ltd., Propionic Acidemia Foundation, Agex Pharma, Gladfem, CSL Behring, Octapharma AG, Sanquin, Kedrion SpA, Shire plc, Vitane Pharmaceuticals Inc.

North America was the largest region in the propionic acidemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in propionic acidemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the propionic acidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The propionic acidemia market includes revenues earned by entities through enzyme replacement therapy (ERT), nutritional therapy services, personalized care management services, patient support programs, and pharmacogenomic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Propionic Acidemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on propionic acidemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for propionic acidemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The propionic acidemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Propionic Acidemia Market Characteristics

3. Propionic Acidemia Market Trends And Strategies

4. Propionic Acidemia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Propionic Acidemia Growth Analysis And Strategic Analysis Framework

6. Propionic Acidemia Market Segmentation

7. Propionic Acidemia Market Regional And Country Analysis

8. Asia-Pacific Propionic Acidemia Market

9. China Propionic Acidemia Market

10. India Propionic Acidemia Market

11. Japan Propionic Acidemia Market

12. Australia Propionic Acidemia Market

13. Indonesia Propionic Acidemia Market

14. South Korea Propionic Acidemia Market

15. Western Europe Propionic Acidemia Market

16. UK Propionic Acidemia Market

17. Germany Propionic Acidemia Market

18. France Propionic Acidemia Market

19. Italy Propionic Acidemia Market

20. Spain Propionic Acidemia Market

21. Eastern Europe Propionic Acidemia Market

22. Russia Propionic Acidemia Market

23. North America Propionic Acidemia Market

24. USA Propionic Acidemia Market

25. Canada Propionic Acidemia Market

26. South America Propionic Acidemia Market

27. Brazil Propionic Acidemia Market

28. Middle East Propionic Acidemia Market

29. Africa Propionic Acidemia Market

30. Propionic Acidemia Market Competitive Landscape And Company Profiles

31. Propionic Acidemia Market Other Major And Innovative Companies

32. Global Propionic Acidemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Propionic Acidemia Market

34. Recent Developments In The Propionic Acidemia Market

35. Propionic Acidemia Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â